Vanguard Fiduciary Trust
CVKD icon

Vanguard Fiduciary Trust’s Cadrenal Therapeutics CVKD Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.8K Hold
8,311
– – ﹤0.01% 3952
2026
Q1 		$42.6K Buy
+8,311
New +$58.3K ﹤0.01% 3856

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
Q1WB
Quest 10 Wealth Builders Fuquay-Varina, Virginia $129M AUM 22.73% 1-Year Est. Return

Vanguard Fiduciary Trust's CVKD Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Cadrenal Therapeutics (CVKD) position steady in Q2 2026 at 8,311 shares worth $27.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3952.

Vanguard Fiduciary Trust first reported a position in CVKD in Q1 2026 and has held it in 2 quarters since. The position peaked at $42.6K in Q1 2026. 20 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • Vanguard Fiduciary Trust held 8,311 shares of Cadrenal Therapeutics worth $27.8K as of Q2 2026.
  • Vanguard Fiduciary Trust left its Cadrenal Therapeutics share count unchanged in Q2 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3952 holding.
  • Vanguard Fiduciary Trust first reported a position in Cadrenal Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Cadrenal Therapeutics position peaked at $42.6K in Q1 2026.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.